Skip to main content

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology

Novel Target: RARA Agonist plus Azacitidine Active in Relapsed or Refractory Acute Myeloid Leukemia

Phoebe Starr

Magrolimab, First CD47 Antibody, Shows Promise in Combination with Azacitidine in Unfit Patients with Acute Myeloid Leukemia

Wayne Kuznar

Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Chase Doyle

Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High- Risk Myelodysplastic Syndromes

Wayne Kuznar

Practice Management

Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life

Chase Doyle

FDA Approvals, Multiple Myeloma, Oncology

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

FDA Approvals, Lung Cancer, Oncology

Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations

FDA Approvals, Lymphoma

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma

Chase Doyle

Practice Management

ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment

Wayne Kuznar

Page 2 of 3
Results 11 - 20 of 27